Archive Newsletter
-
04.03.24 -- Reducing Clinical Holds On CGT: Approaches For Sponsors And The FDA
4/3/2024
04/03/24 Cell & Gene Newsletter
-
04.02.24 -- CRISPR Therapies And The Regulatory Landscape
4/2/2024
04/02/24 Cell & Gene Newsletter
-
04.01.24 -- See how Organ-Chips are Transforming Drug Development for Cancer, Toxicology, Cell & Gene Therapy, and More!
4/1/2024
04/01/24
-
04.01.24 -- Improving AAV Purity Upstream With PCL Manufacturing
4/1/2024
04/01/24
-
03.28.24 -- Developing Cell & Gene Therapies: Optimization-By-Design, Analytical Ultracentrifugation, Candidate Screening, And Feasibility Studies
3/28/2024
03/28/24 Cell & Gene Newsletter
-
03.28.24 -- What Does It Take To Make Higher Quality AAV?
3/28/2024
03/28/24 Cell & Gene Newsletter
-
03.27.24 -- Global Observations In The Clinical Trial Landscape
3/27/2024
03/27/24 Cell & Gene Newsletter
-
03.27.24 -- Inside Cellular Rejuvenation Therapies For Age-Related Diseases
3/27/2024
03/27/24 Cell & Gene Newsletter
-
03.26.24 -- FDA's 2024 Regulatory Outlook Recap
3/26/2024
03/26/24 Cell & Gene Newsletter
-
03.25.24 -- Optimizing CGT Development: Modular Approaches And Cryopreservation Insights
3/25/2024
03/25/24 Cell & Gene Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more